It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
In vitro, spheroid models have become well established in cancer research because they can better mimic certain characteristics of in vivo tumours. However, interaction with the tumour microenvironment, such as cancer-associated fibroblasts, plays a key role in tumour progression. We initially focused on the interaction of tumour cells with fibroblasts. To model this interaction, we developed a spheroid model of ovarian cancer and fibroblasts. To this end, ovarian cancer cell lines and ex vivo primary cells were simultaneously and sequentially seeded with fibroblasts in a scaffold-free system at different ratios and subsequently characterized with respect to changes in morphology, proliferation, and viability. We demonstrated that co-cultures are able to form by far more compact spheroids, especially in cells that form aggregates in mono-culture. In addition, the co-cultures were able to increase proliferation and sensitivity to cisplatin. Simultaneous seeding led fibroblasts invade the core in both cell lines and primary cells. These results show differences in formation, firmness, and size between co-culture and mono-culture. Our model is designed to better represent and characterize the mutual influencing factors of fibroblasts and tumour cells. Fibroblast-supplemented multicellular spheroids are a valuable tool for tumour microenvironment interaction and new drug discovery.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University and University Medical Center Schleswig-Holstein Campus Kiel, Department of Gynaecology and Obstetrics, Kiel, Germany (GRID:grid.412468.d) (ISNI:0000 0004 0646 2097); Kiel University, KiNSIS Priority Research Area, Kiel, Germany (GRID:grid.9764.c) (ISNI:0000 0001 2153 9986)
2 University and University Medical Center Schleswig-Holstein Campus Kiel, Department of Gynaecology and Obstetrics, Kiel, Germany (GRID:grid.412468.d) (ISNI:0000 0004 0646 2097)
3 University and University Medical Center Schleswig-Holstein Campus Kiel, Department of Pathology, Kiel, Germany (GRID:grid.412468.d) (ISNI:0000 0004 0646 2097)
4 Kiel University, Department of Pharmaceutics and Biopharmaceutics, Kiel, Germany (GRID:grid.9764.c) (ISNI:0000 0001 2153 9986); Kiel University, KiNSIS Priority Research Area, Kiel, Germany (GRID:grid.9764.c) (ISNI:0000 0001 2153 9986)
5 University and University Medical Center Schleswig-Holstein Campus Kiel, Institute of Medical Informatics and Statistics, Kiel, Germany (GRID:grid.412468.d) (ISNI:0000 0004 0646 2097)
6 University and University Medical Center Schleswig-Holstein Campus Kiel, Department of Gynaecology and Obstetrics, Kiel, Germany (GRID:grid.412468.d) (ISNI:0000 0004 0646 2097); Jena University Hospital, Department of Gynaecology, Jena, Germany (GRID:grid.275559.9) (ISNI:0000 0000 8517 6224)